Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy - PubMed
- ️Thu Jan 01 2015
Review
. 2015 Mar 15;559(1):31-7.
doi: 10.1016/j.gene.2015.01.010. Epub 2015 Jan 10.
Affiliations
- PMID: 25582275
- DOI: 10.1016/j.gene.2015.01.010
Review
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy
Xiangxiang Ding et al. Gene. 2015.
Abstract
Background: The aim of this study was to ascertain whether single nucleotide polymorphisms of cytidine deaminase (CDA), a key enzyme in the metabolism pathway of gemcitabine, could predict clinical outcomes of cancer patients with gemcitabine-based chemotherapy.
Methods: We searched MEDLINE and EMBASE up to January 2013 to identify eligible studies. A rigorous quality assessment of eligible studies was conducted according to the Newcastle-Ottawa Quality Assessment Scale. For each included study, the overall survival (OS), overall response rate (ORR) and toxicities were extracted and pooled using random-effects model.
Results: In total, data from 13 studies were included. CDA 208A>G and CDA 435C>T were not included in quantified synthesis due to limited data. CDA 79A>C polymorphism was not significantly associated with OS; however, patients carrying the variant CDA 79C allele were likely to have a poor survival, hazard ratio (HR)=1.03, 95% CI 0.957-1.27 (AC+CC vs. AA). CDA 79A>C polymorphism did not correlated with ORR, odds ratio (OR)=0.719, 95% CI 0.363-1.425 (AC+CC vs. AA). However, patients with the variant CDA 79C allele would experience more grade ≥ 3 leucopenia (OR=2.933, 95% CI 1.357-6.605) and tended to have more severe neutropenia (OR=1.313, 95% CI 0.157-10.981).
Conclusions: These results suggest that CDA 79A>C polymorphisms is a potential biomarker for toxicity of gemcitabine-based chemotherapy and a CDA testing before gemcitabine administration is preferred.
Keywords: Chemotherapy; Cytidine deaminase; Gemcitabine; Single nucleotide polymorphism.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Li J, Xu D, Huang J, Wang YN, Ma XP, Lin ZY, Gong P. Li J, et al. Int J Biol Markers. 2019 Dec;34(4):389-397. doi: 10.1177/1724600819882940. Epub 2019 Oct 11. Int J Biol Markers. 2019. PMID: 31603383
-
Metharom E, Galettis P, Manners S, Jelinek M, Liauw W, de Souza PL, Hoskins JM, Links M. Metharom E, et al. Asia Pac J Clin Oncol. 2011 Mar;7(1):65-74. doi: 10.1111/j.1743-7563.2010.01354.x. Epub 2010 Dec 30. Asia Pac J Clin Oncol. 2011. PMID: 21332653 Clinical Trial.
-
Xu J, Zhou Y, Zhang J, Chen Y, Zhuang R, Liu T, Cai W. Xu J, et al. Clin Chim Acta. 2012 Aug 16;413(15-16):1284-7. doi: 10.1016/j.cca.2012.04.018. Epub 2012 Apr 23. Clin Chim Acta. 2012. PMID: 22546611
-
Li H, Wang X, Wang X. Li H, et al. Int J Biol Markers. 2014 Jul-Sep;29(3):e224-32. doi: 10.5301/jbm.5000076. Epub 2014 Feb 13. Int J Biol Markers. 2014. PMID: 24557790 Review.
-
[Pharmacogenomic research for avoiding adverse reactions by anti-cancer drugs].
Saito Y. Saito Y. Yakugaku Zasshi. 2011 Feb;131(2):239-46. doi: 10.1248/yakushi.131.239. Yakugaku Zasshi. 2011. PMID: 21297369 Review. Japanese.
Cited by
-
Mell LK, Xu R, Yashar CM, McHale MT, Einck JP, Mayadev J, Lee E, Binder P, Rash D, Eskander R, Heide ES, Plaxe SC, Mundt AJ, Saenz CC. Mell LK, et al. Int J Radiat Oncol Biol Phys. 2020 Aug 1;107(5):964-973. doi: 10.1016/j.ijrobp.2020.04.019. Epub 2020 Apr 22. Int J Radiat Oncol Biol Phys. 2020. PMID: 32334034 Free PMC article. Clinical Trial.
-
Emran TB, Shahriar A, Mahmud AR, Rahman T, Abir MH, Siddiquee MF, Ahmed H, Rahman N, Nainu F, Wahyudin E, Mitra S, Dhama K, Habiballah MM, Haque S, Islam A, Hassan MM. Emran TB, et al. Front Oncol. 2022 Jun 23;12:891652. doi: 10.3389/fonc.2022.891652. eCollection 2022. Front Oncol. 2022. PMID: 35814435 Free PMC article. Review.
-
Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
Awad S, Alkashash AM, Amin M, Baker SJ, Rose JB. Awad S, et al. Front Oncol. 2020 May 12;10:620. doi: 10.3389/fonc.2020.00620. eCollection 2020. Front Oncol. 2020. PMID: 32477933 Free PMC article. Review.
-
Saiki Y, Hirota S, Horii A. Saiki Y, et al. Cancer Drug Resist. 2020 Oct 12;3(4):819-831. doi: 10.20517/cdr.2020.39. eCollection 2020. Cancer Drug Resist. 2020. PMID: 35582220 Free PMC article. Review.
-
Hryciuk B, Szymanowski B, Romanowska A, Salt E, Wasąg B, Grala B, Jassem J, Duchnowska R. Hryciuk B, et al. Oncol Lett. 2018 Feb;15(2):1912-1916. doi: 10.3892/ol.2017.7473. Epub 2017 Nov 22. Oncol Lett. 2018. PMID: 29434889 Free PMC article.